

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4004537
<b>Application Number:</b>	09823699
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7451
<b>Title of Invention:</b>	AIDS virus vaccines using sendai virus vector
<b>First Named Inventor/Applicant Name:</b>	Munehide Kano
<b>Customer Number:</b>	21559
<b>Filer:</b>	Michael A. Robinson/Terese Miffitt
<b>Filer Authorized By:</b>	Michael A. Robinson
<b>Attorney Docket Number:</b>	50026/022002
<b>Receipt Date:</b>	25-SEP-2008
<b>Filing Date:</b>	30-MAR-2001
<b>Time Stamp:</b>	14:36:34
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	14855
Deposit Account	032095
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	50026_022002_communication_regarding_IDS.pdf	419131 8b12166f4236c19c1fcd4b48f1e9d36672e77	no	8

### Warnings:

### Information:

2	Information Disclosure Statement Letter	50026_022002_supplemental_IDS.pdf	45725 55f66653d31a08b711a8de3c8b9f55f8d3e1602f	no	1
---	---	-----------------------------------	---	----	---

### Warnings:

### Information:

3	Information Disclosure Statement (IDS) Filed (SB/08)	50026_022002_1449.pdf	39937 1a12efc0de1753cd48b4f7b5c68a3e0d48f1c9b	no	1
---	--	-----------------------	--	----	---

### Warnings:

### Information:

This is not an USPTO supplied IDS fillable form

4	Fee Worksheet (PTO-06)	fee-info.pdf	29791 afcc08f086a210486a67251a7c1b5a251c3a9029	no	2
---	------------------------	--------------	---	----	---

### Warnings:

### Information:

Total Files Size (in bytes):	534584
------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

### New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

### National Stage of an International Application under 35 U.S.C. 371

If a timely submission is being filed and the international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

### New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.